CD4 and neoplasm: Despite the recognition that MHC-II is significant for tumor neoantigen presentation and priming of CD4+ T cells (141) and for immunotherapy outcomes (142), the accuracy and precision of MHC-II epitope predictions are poor when compared to class I (143).